History Says to Buy These Space Stocks in a Market Crash

The article flags elevated valuation and loss-making risks at SpaceX and Rocket Lab, while arguing that a major market pullback could create buying opportunities. SpaceX is cited at a roughly $1.92 trillion market capitalization and 43 times expected sales, despite analyst-projected revenue growth of about 141% this year from $18.7 billion last year; Rocket Lab grew Q2 revenue about 62% year over year to $234 million and trades at roughly 32 times expected sales. Both companies are still operating at a loss, and the market-crash scenario is presented as a possibility rather than a forecast.

Analysis

The key risk is not simply multiple compression: a broad selloff can also raise the cost of capital and delay customer programs, weakening the growth and scale assumptions that support both equities. That feedback loop matters most for Rocket Lab, where the investment case depends on converting launch activity into better unit economics; a cheaper share price alone does not improve margins or fund execution. Conversely, government and defense demand could make parts of the launch market less cyclical than speculative technology spending, but backlog quality, contract timing, and cash conversion need verification.

Treat the article’s company-level forecasts and valuation inputs as claims to validate, not investment-grade underwriting. For SpaceX, clarify the scope of reported revenue and the cash burden of its multiple concurrent projects; a large revenue forecast does not resolve loss-making economics or capital intensity. For Rocket Lab, track gross-margin progression, cash burn, launch cadence, and development milestones. A market drawdown could create an entry point, but could also expose financing or execution risk.

The contrarian angle: waiting for a crash may miss company-specific catalysts, while buying indiscriminately into a crash assumes financing conditions and demand recover quickly. Near term, no trade is justified by this article alone. Over 1–3 months, monitor rates, risk appetite, and company disclosures; over 6–18 months, economics and execution—not headline growth—should determine relative winners.

Key Decisions for Investors

• Keep SPCX and RKLB on a staged-entry watchlist rather than buying solely on a broad-market drawdown. Require a valuation reset plus evidence that operating milestones remain intact; do not assume a lower multiple repairs weak cash economics.
• For RKLB, verify gross-margin trend, cash burn, backlog conversion, launch cadence, and development milestones before adding. A worsening margin trajectory or funding pressure would falsify the pullback-buy thesis; improving unit economics would strengthen it.
• For SPCX, verify the scope and reliability of revenue estimates, project-level capital requirements, and cash generation. If capex accelerates without corresponding cash-flow progress, treat the selloff as possible fundamental repricing rather than a temporary sentiment dislocation.
• Monitor bond yields and financing conditions as near-term risk signals. A sharp rise in yields or deterioration in risk appetite could pressure both high-duration names; sustained easing without weakening company execution would improve the entry setup.